Physician profile
Benjamin O Camacho
NPI 1699759936
$12,837.27
in general payments reported to CMS, 2019-2025
40 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,381 · 2020: $1,186 · 2021: $2,079 · 2022: $2,379 · 2023: $2,328 · 2024: $1,602 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,808 · Education: $4.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,807.62 |
| Education | $4.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,539.86 | 2019-2023 | Watchman Access System, Watchman Flx |
| Medtronic, INC. | $1,171.44 | 2021-2024 | Micra, Crome Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $1,126.87 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,115.29 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $977.08 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $838.90 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $776.01 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $707.07 | 2021-2025 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $615.63 | 2023-2025 | |
| Abbott Laboratories | $586.82 | 2019-2024 | Gallant, Aveir, Amplatzer Talisman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.79 | 2019-2023 | Lifevest |
| Pfizer INC. | $354.05 | 2019-2025 | |
| Medtronic Vascular, INC. | $321.44 | 2019-2020 | |
| Biotronik INC. | $247.05 | 2019 | |
| Radius Health, INC. | $245.10 | 2022-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $210.92 | 2019 | |
| Ge Healthcare | $192.28 | 2024 | |
| Amarin Pharma, INC. | $172.06 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $155.33 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $138.19 | 2023-2025 | Assure Wcd |
| Sunovion Pharmaceuticals INC. | $118.21 | 2019 | |
| Novo Nordisk INC | $100.43 | 2021-2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $86.15 | 2022-2023 | Eliquis |
| Abiomed | $74.18 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $60.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.28 | 2019-2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $55.34 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $48.72 | 2019-2025 | Evkeeza |
| Impulse Dynamics (USA) INC. | $48.58 | 2022 | |
| Daiichi Sankyo INC. | $46.78 | 2020-2021 | |
| Edwards Lifesciences Corporation | $46.73 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $45.36 | 2023-2025 | |
| Amgen INC. | $41.74 | 2022 | |
| Esperion Therapeutics, INC. | $40.47 | 2020-2021 | |
| Genzyme Corporation | $19.34 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.49 | 2025 | Edarbi |
| Abbvie INC. | $17.24 | 2021 | |
| Baxter Healthcare | $14.84 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $14.42 | 2023 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.